Expression of BCL-6 Protein, CD138/syndecan-1 (syn-1), and LMP-1 in AIDS-Related Systemic NHLs
| Case-150 . | Diagnosis . | Immunohistochemistry-151 . | Viral Infections . | c-MYC . | BCL-6 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Working Formulation . | REAL Classification . | BCL-6 (%) . | syn-1 (%) . | LMP-1 (%) . | EBV-152 . | KSHV-152 . | Genetic Lesions . | Rearrangements . | Mutations . | |
| 1 | LNCCL | DLCL | >75 | 0 | 0 | + | − | ND | ND | ND |
| 2 | LNCCL | DLCL | >75 | 0 | 0 | − | ND | ND | ND | ND |
| 3 | LNCCL | DLCL | 50-75 | 0 | 0 | + | ND | ND | ND | ND |
| 4 | LNCCL | DLCL | 50-75 | 0 | 0 | − | − | − | − | + |
| 5 | LNCCL | DLCL | >75 | 0 | 0 | − | − | ND | ND | ND |
| 6 | LNCCL | DLCL | >75 | 0 | 0 | − | − | − | ND | + |
| 7 | LNCCL | DLCL | 10-25 | 0 | 0 | − | − | − | − | + |
| 8 | IBLP | DLCL | 10-25 | 0 | 0 | + | − | − | ND | + |
| 9 | IBLP | DLCL | 0 | <10 | <10 | + | − | − | − | + |
| 10 | IBLP | DLCL | 0 | 50-75 | 10-25 | + | − | + | − | − |
| 11 | IBLP | DLCL | 0 | 10-25 | 10-25 | + | − | ND | ND | ND |
| 12 | IBLP | DLCL | 0 | <10 | 25-50 | + | ND | ND | ND | ND |
| 13 | IBLP | DLCL | 0 | 10-25 | 25-50 | + | − | + | − | ND |
| 14 | IBLP | DLCL | 50-75 | 0 | 0 | − | − | − | ND | − |
| 15 | IBLP | DLCL | 0 | 50-75 | 0 | − | ND | ND | ND | ND |
| 16 | IBLP | DLCL | 0 | 0 | 0 | − | − | ND | ND | ND |
| 17 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | + |
| 18 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | + |
| 19 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | ND | ND | ND |
| 20 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | − |
| 21 | SNCCL | Burkitt's | 50-75 | 0 | 0 | + | − | + | − | − |
| 22 | SNCCL | Burkitt's | 25-50 | 0 | 0 | + | − | + | ND | + |
| 23 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | ND | ND | − |
| 24 | SNCCL | Burkitt's | 10-25 | 0 | 0 | − | − | + | − | + |
| 25 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | + | − | + |
| 26 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | + | − | + |
| 27 | SNCCL | Burkitt's | 50-75 | 0 | 0 | − | ND | ND | ND | ND |
| Case-150 . | Diagnosis . | Immunohistochemistry-151 . | Viral Infections . | c-MYC . | BCL-6 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Working Formulation . | REAL Classification . | BCL-6 (%) . | syn-1 (%) . | LMP-1 (%) . | EBV-152 . | KSHV-152 . | Genetic Lesions . | Rearrangements . | Mutations . | |
| 1 | LNCCL | DLCL | >75 | 0 | 0 | + | − | ND | ND | ND |
| 2 | LNCCL | DLCL | >75 | 0 | 0 | − | ND | ND | ND | ND |
| 3 | LNCCL | DLCL | 50-75 | 0 | 0 | + | ND | ND | ND | ND |
| 4 | LNCCL | DLCL | 50-75 | 0 | 0 | − | − | − | − | + |
| 5 | LNCCL | DLCL | >75 | 0 | 0 | − | − | ND | ND | ND |
| 6 | LNCCL | DLCL | >75 | 0 | 0 | − | − | − | ND | + |
| 7 | LNCCL | DLCL | 10-25 | 0 | 0 | − | − | − | − | + |
| 8 | IBLP | DLCL | 10-25 | 0 | 0 | + | − | − | ND | + |
| 9 | IBLP | DLCL | 0 | <10 | <10 | + | − | − | − | + |
| 10 | IBLP | DLCL | 0 | 50-75 | 10-25 | + | − | + | − | − |
| 11 | IBLP | DLCL | 0 | 10-25 | 10-25 | + | − | ND | ND | ND |
| 12 | IBLP | DLCL | 0 | <10 | 25-50 | + | ND | ND | ND | ND |
| 13 | IBLP | DLCL | 0 | 10-25 | 25-50 | + | − | + | − | ND |
| 14 | IBLP | DLCL | 50-75 | 0 | 0 | − | − | − | ND | − |
| 15 | IBLP | DLCL | 0 | 50-75 | 0 | − | ND | ND | ND | ND |
| 16 | IBLP | DLCL | 0 | 0 | 0 | − | − | ND | ND | ND |
| 17 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | + |
| 18 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | + |
| 19 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | ND | ND | ND |
| 20 | SNCCL | Burkitt's | >75 | 0 | 0 | + | − | + | − | − |
| 21 | SNCCL | Burkitt's | 50-75 | 0 | 0 | + | − | + | − | − |
| 22 | SNCCL | Burkitt's | 25-50 | 0 | 0 | + | − | + | ND | + |
| 23 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | ND | ND | − |
| 24 | SNCCL | Burkitt's | 10-25 | 0 | 0 | − | − | + | − | + |
| 25 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | + | − | + |
| 26 | SNCCL | Burkitt's | >75 | 0 | 0 | − | − | + | − | + |
| 27 | SNCCL | Burkitt's | 50-75 | 0 | 0 | − | ND | ND | ND | ND |
Abbreviations: syn-1, CD138/syndecan-1; REAL, revised European-American Classification of Lymphoid Neoplasms; SNCCL, small noncleaved cell lymphoma; LNCCL, large noncleaved cell lymphoma; IBLP, immunoblastic lymphoma plasmacytoid; DLCL, diffuse large cell lymphoma; LMP-1, latent membrane protein-1; EBV, Epstein-Barr virus; KSHV, Kaposi's sarcoma associated herpesvirus; ND, not done; +, positive; −, negative.
Pathologic samples derived from patients are indicated by numbers.
The percentage of BCL-6, syn-1, and LMP-1+neoplastic cells was assigned to one of the following categories: 0, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.
Tumor cell infection as defined by a combination of in situ hybridization, Southern blot analysis, and PCR studies.